LifeMD, Inc. (LFMD)
| Market Cap | 146.05M -49.9% |
| Revenue (ttm) | 191.59M +20.8% |
| Net Income | -2.91M |
| EPS | -0.09 |
| Shares Out | 48.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,025,106 |
| Open | 2.910 |
| Previous Close | 2.955 |
| Day's Range | 2.910 - 3.065 |
| 52-Week Range | 2.560 - 7.320 |
| Beta | 2.04 |
| Analysts | Strong Buy |
| Price Target | 8.13 (+168.32%) |
| Earnings Date | Aug 5, 2026 |
About LFMD
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men’s telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men’s health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications,... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LFMD stock is "Strong Buy." The 12-month stock price target is $8.13, which is an increase of 168.32% from the latest price.
News
LifeMD price target lowered to $5 from $8 at KeyBanc
KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on LifeMD (LFMD) to $5 from $8 and keeps an Overweight rating on the shares.
LifeMD price target lowered to $9 from $10 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on LifeMD (LFMD) to $9 from $10 and keeps a Buy rating on the shares. The company reported a sales…
LifeMD price target lowered to $8 from $10 at B. Riley
B. Riley analyst Anderson Schock lowered the firm’s price target on LifeMD (LFMD) to $8 from $10 and keeps a Buy rating on the shares following the company’s Q2 report…
LifeMD price target lowered to $5 from $8 at Lake Street
Lake Street lowered the firm’s price target on LifeMD (LFMD) to $5 from $8 and keeps a Buy rating on the shares after the company reported “soft” Q2 results and…
LifeMD price target lowered to $7 from $8 at Mizuho
Mizuho lowered the firm’s price target on LifeMD (LFMD) to $7 from $8 and keeps an Outperform rating on the shares.
LifeMD price target lowered to $9 from $10 at BTIG
BTIG lowered the firm’s price target on LifeMD (LFMD) to $9 from $10 and keeps a Buy rating on the shares. LifeMD reported a weaker-than-expected Q2 with lower revenue and…
UPDATE - LifeMD Reports Second Quarter 2026 Results
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA...
LifeMD sees Q3 revenue $48M-$51M, consensus $58.55M
Sees Q3 adjusted EBITDA loss of $1M to gain of $2M. “This transition to branded GLP-1 medications has weighed on near-term profitability, but it has produced a fundamentally stronger company…
LifeMD cuts FY26 revenue view to $205.5M-$212.5M from $220M-$230M
Consensus $222.05M. Cuts FY26 revenue view to loss of $6B to break even from $12M-$17M. “The second quarter reflected the planned step-down in marketing investment we described on our last…
LifeMD reports Q2 EPS (16c), consensus (5c)
Reports Q2 revenue $47.3M, consensus $49.1M. “Revenue of $47.3 million came in within our guidance range, and while adjusted EBITDA finished below the range we guided to, it improved approximately…
LifeMD Earnings Call Transcript: Q2 2026
Q2 revenue was $47.3M, with gross margin expanding to 89% and recurring bill revenue at 84%. Strategic shifts to branded therapies, longer memberships, and diversified acquisition channels led to a revised 2026 outlook, but profitability is expected to improve in H2.
LifeMD Earnings release: Q2 2026
LifeMD released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
LifeMD Slides: Q2 2026
LifeMD has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
LifeMD Quarterly report: Q2 2026
LifeMD has published its Q2 2026 quarterly earnings report on August 5, 2026.
LifeMD to Report Second Quarter 2026 Financial Results on August 5
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six mont...
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to h...
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
LifeMD (LFMD) announced a strategic co-marketing collaboration with Antares Pharma, a subsidiary of Halozyme (HALO), supporting a direct-to-patient self-pay program for Xyosted. Under the agreement, L...
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, l...
LifeMD appoints Umesh Sripad as chief technology officer
LifeMD (LFMD) announced the appointment of Umesh Sripad as chief technology officer, or CTO, effective immediately. In this role, Sripad will lead LifeMD’s technology strategy, platform transformation...
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD's Next Phase of Growth Seasoned Technology Executive Brings More Than Two ...
LifeMD Transcript: 16th Annual LD Micro Invitational Conference
A leading virtual care provider is expanding from men's health into high-growth areas like GLP-1 weight management, women's health, psychiatry, and cardiology, leveraging proprietary AI and integrated pharmacy infrastructure. Strong revenue growth, high margins, and a shift toward insurance coverage position the business for continued expansion and profitability.
LifeMD to Participate in Upcoming Investor Conferences
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming inve...
LifeMD Slides: Investor presentation
LifeMD has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
LifeMD reports Q1 EPS (20c), consensus (12c)
Reports Q1 revenue $50.16M, consensus $48.88M. “Q1 was a strong start to 2026. We added more than 42,000 net telehealth subscribers, the largest quarterly net addition in our history. We…
LifeMD sees Q2 revenue $47M-$50M, consensus $53.74M
Sees Q2 adjusted EBITDA loss of $2M to gain of $1M.